Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001144204-19-045806
Filing Date
2019-09-24
Accepted
2019-09-24 17:01:16
Documents
1
Period of Report
2019-09-22

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tv530009_4.html 4  
1 OWNERSHIP DOCUMENT tv530009_4.xml 4 4144
  Complete submission text file 0001144204-19-045806.txt   5788
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O BRAINSTORM CELL THERAPEUTICS INC., 3 UNIVERSITY PLAZA DRIVE, STE 320 HACKENSACK NJ 07601
Business Address
Rubin Eyal (Reporting) CIK: 0001721411 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 191111393